CAR-T and Cell Therapy: a 23-Company FUZKK Utility Map
This article converts the company list from the supplied infographic into a practical map of existing FUZKK utilities. The 1–23 order is retained from the image but is not presented as an independently verified market ranking.
Existing packages used
Four independent layers
Company → four FUZKK layers
Commercial platforms with direct product-specific fit · 4
1. Johnson & Johnson · United States
Commercial autologous BCMA CAR-T therapy; a direct fit exists for ciltacabtagene autoleucel.
2. Gilead Sciences / Kite · United States
Commercial autologous CD19 CAR-T workflows; a direct fit exists for axicabtagene ciloleucel.
3. Bristol Myers Squibb · United States
Commercial CD19 and BCMA programmes; direct fits exist for lisocabtagene maraleucel and idecabtagene vicleucel.
4. Novartis · Switzerland
Commercial CD19 CAR-T platform; a direct fit exists for tisagenlecleucel.
Regional commercial and clinical CAR-T developers · 5
5. Autolus Therapeutics · United Kingdom
Autologous programmable T-cell therapies; no exact obe-cel checker exists in the current FUZKK catalogue, so mapping remains class-level.
6. JW Therapeutics · China
Autologous CD19 CAR-T platform and localised manufacturing; no exact relma-cel checker is claimed.
7. ImmunoACT · India
Autologous CD19 CAR-T therapy and a local manufacturing chain; workflow-level mapping is used.
9. IASO Biotherapeutics · China
Clinical CAR-T programmes including BCMA-directed work; class-level release, potency and sterile-workflow mapping is used.
10. Immuneel Therapeutics · India
Cell and gene therapy focused on access and local clinical-manufacturing infrastructure.
Allogeneic, gene-edited and off-the-shelf platforms · 7
11. Wugen · United States
Allogeneic/off-the-shelf CAR-T and gene-editing workflows. The name is retained exactly as shown in the source infographic.
13. Allogene Therapeutics · United States
Allogeneic CAR-T and off-the-shelf manufacturing, with emphasis on donor material, gene editing, comparability and release readiness.
16. Cellectis · France
Gene-edited allogeneic CAR-T platform; identity, RCV, residuals, donor/supplier control and risk-control traceability are particularly relevant.
18. Atara Biotherapeutics · United States
Allogeneic T-cell/cell-therapy platform adjacent to CAR-T manufacturing controls; mapping is limited to applicable workflow utilities.
19. Caribou Biosciences · United States
CRISPR genome-edited allogeneic CAR-T platform, with stronger fit for editing traceability, identity, residuals and release controls.
21. CRISPR Therapeutics · Switzerland / United States
CRISPR-engineered allogeneic CAR-T and emerging in-vivo approaches; an enhanced gene-editing and software/data traceability layer applies.
22. Poseida Therapeutics · United States
Allogeneic CAR-T and genetic-medicine platform; Roche completed the acquisition on 8 January 2025.
Next-generation, BCMA, CNS and solid-tumour programmes · 4
8. CARsgen Therapeutics · China
CAR-T platforms for haematological and solid tumours, including autologous and allogeneic approaches; no exact product checker is claimed.
14. Lyell Immunopharma · United States
Next-generation T-cell engineering and solid-tumour programmes; platform/workflow mapping is used rather than a product-specific claim.
17. BrainChild Bio · United States
CAR-T/cell-therapy programmes for CNS and solid-tumour contexts; class-level potency, identity and sterile-release mapping is required.
20. Arcellx · United States
BCMA-directed cell-therapy platform; the company became part of Gilead in April 2026. No exact anito-cel checker is claimed in the current catalogue.
Autoimmune and alternative-engineering cell-therapy programmes · 3
12. Cartesian Therapeutics · United States
RNA/mRNA-engineered cell therapy and autoimmune programmes; vector-specific checks apply only where the actual process uses a vector.
15. Kyverna Therapeutics · United States
CAR-T therapies for B-cell-driven autoimmune diseases in autologous and allogeneic formats.
23. Cabaletta Bio · United States
CD19 CAR-T for autoimmune diseases; class-level mapping covers potency, viability, sterile release and lifecycle controls.
Public links used to verify company profiles
These links support manual verification before publication and outreach. The image remains the primary source for list membership; public pages help avoid assigning a product or status that is not supported.
- 1. Johnson & Johnson · United States
- 2. Gilead Sciences / Kite · United States
- 3. Bristol Myers Squibb · United States
- 4. Novartis · Switzerland
- 5. Autolus Therapeutics · United Kingdom
- 6. JW Therapeutics · China
- 7. ImmunoACT · India
- 8. CARsgen Therapeutics · China
- 9. IASO Biotherapeutics · China
- 10. Immuneel Therapeutics · India
- 11. Wugen · United States
- 12. Cartesian Therapeutics · United States
- 13. Allogene Therapeutics · United States
- 14. Lyell Immunopharma · United States
- 15. Kyverna Therapeutics · United States
- 16. Cellectis · France
- 17. BrainChild Bio · United States
- 18. Atara Biotherapeutics · United States
- 19. Caribou Biosciences · United States
- 20. Arcellx · United States
- 21. CRISPR Therapeutics · Switzerland / United States
- 22. Poseida Therapeutics · United States
- 23. Cabaletta Bio · United States